Intevac Announces Fourth Quarter and Full Year 2019 Financial Results
Wed, January 29 2020
Fiscal 2019 Highlights
-
Photonics Business
- Revenues grew 37% year-over-year
-
Record
$40M order received in support of digital night vision programs forU.S. Government - Strong ramp of development revenues for IVAS program, the first all-digital solution for the ground soldier
-
Record year-end backlog of
$71M , up 62% over year-end 2018
-
Thin-film Equipment Business
- Revenues grew 6% year-over-year
- Successful installation of VERTEX Spectra™ evaluation system with Tier 1 display cover glass manufacturer
- Introduced new VERTEX Marathon™ high-productivity platform, enabling ultra-durable DiamondClad™ protective coatings for the display cover glass market
- Delivery of nine ENERGi® systems for high-efficiency solar cell manufacturing
- Successful installation of our first MATRIX® PVD evaluation system for advanced semiconductor packaging
-
Financial Performance
- With year-over-year revenue growth of 14%, gross profit increased 25% over 2018, with higher gross margins in both TFE and Photonics
-
With R&D and SG&A expenses held flat year-over-year, operating income grew to
$4M -
Return to profitability, with full-year earnings of
$0.05 per share exceeding prior guidance -
Positive cash flow from operations for the year, with a year-end balance of
$42.8 million in total cash, restricted cash and investments, an increase of$2.5M over 2018
“We are very pleased to report a profitable year of growth for 2019, with continued momentum executing against our strategic growth initiatives,” commented
“We achieved a number of significant milestones in 2019, in support of our long-term growth initiatives,” continued
“Each of these milestones supports the long-term revenue growth and profitability objectives for Intevac,” concluded
($ Millions, except per share amounts) |
Q4 2019 |
Q4 2018 |
||||||||||||
GAAP Results |
Non-GAAP Results |
GAAP Results |
Non-GAAP Results |
|||||||||||
Net Revenues |
$ |
35.4 |
$ |
35.4 |
$ |
31.6 |
|
$ |
31.6 |
|
||||
Operating Income |
$ |
7.3 |
$ |
7.3 |
$ |
1.9 |
|
$ |
1.8 |
|
||||
Net Income |
$ |
5.2 |
$ |
5.2 |
$ |
10.0 |
|
$ |
1.9 |
|
||||
Net Income per Diluted Share |
$ |
0.22 |
$ |
0.22 |
$ |
0.44 |
|
$ |
0.08 |
|
||||
|
Year Ended |
Year Ended |
||||||||||||
|
|
|||||||||||||
GAAP Results |
Non-GAAP Results |
GAAP Results |
Non-GAAP Results |
|||||||||||
Net Revenues |
$ |
108.9 |
$ |
108.9 |
$ |
95.1 |
|
$ |
95.1 |
|
||||
Operating Income (Loss) |
$ |
3.9 |
$ |
3.9 |
$ |
(4.2 |
) |
$ |
(4.3 |
) |
||||
Net Income (Loss) |
$ |
1.1 |
$ |
1.1 |
$ |
3.6 |
|
$ |
(4.4 |
) |
||||
Net Income (Loss) per Diluted Share |
$ |
0.05 |
$ |
0.05 |
$ |
0.16 |
|
$ |
(0.19 |
) |
Intevac’s non-GAAP adjusted results exclude where applicable: (1) changes in fair value of contingent consideration liabilities associated with business combinations; (2) restructuring charges and (3) the reversal of a deferred tax asset valuation allowance. A reconciliation of the GAAP and non-GAAP adjusted results is provided in the financial table included in this release. See also “Use of Non-GAAP Financial Measures” section.
Fourth Quarter Fiscal 2019 Summary
Net income for the quarter was
Revenues were
TFE gross margin was 46.9% compared to 30.6% in the fourth quarter of 2018 and 28.2% in the third quarter of 2019. The improvement from the fourth quarter of 2018 and the third quarter of 2019 was primarily due to favorable product mix. Photonics gross margin was 45.7% compared to 42.1% in the fourth quarter of 2018 and 43.1% in the third quarter of 2019. The improvement from the fourth quarter of 2018 and the third quarter of 2019 was primarily due to improved margins on research and development contracts. Consolidated gross margin was 46.5%, compared to 33.5% in the fourth quarter of 2018 and 33.4% in the third quarter of 2019.
R&D and SG&A expenses were
Order backlog totaled
The Company ended the year with
Fiscal Year 2019 Summary
Net income was
Revenues were
TFE gross margin was 37.2%, compared to 36.5% in 2018, while Photonics gross margin was 38.3%, compared to 28.6% in 2018. Consolidated gross margin was 37.5% compared to 34.4% in 2018. The improvement from 2018 was primarily due to higher revenue levels and improved margins on research and development contracts. Total R&D and SG&A expenses were relatively flat at
Use of Non-GAAP Financial Measures
Management uses non-GAAP results to evaluate the Company’s operating and financial performance in light of business objectives and for planning purposes. These measures are not in accordance with GAAP and may differ from non-GAAP methods of accounting and reporting used by other companies.
Conference Call Information
The Company will discuss its financial results and outlook in a conference call today at
About
In our Thin-film Equipment business, we are a leader in the design and development of high-productivity, thin-film processing systems. Our production-proven platforms are designed for high-volume manufacturing of substrates with precise thin film properties, such as the hard drive media, display cover panel, and solar photovoltaic markets we serve currently.
In our Photonics business, we are a recognized leading developer of advanced high-sensitivity digital sensors, cameras and systems that primarily serve the defense industry. We are the provider of integrated digital imaging systems for most
For more information call 408-986-9888, or visit the Company's website at www.intevac.com.
200 Lean®, INTEVAC MATRIX®, INTEVAC VERTEX®, and ENERGi® are registered trademarks and DiamondClad™, VERTEX Marathon™, VERTEX Spectra™ are trademarks of
Safe Harbor Statement
This press release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”).
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in thousands, except percentages and per share amounts) |
|
|||||||||||||||
|
Three months ended |
Year ended |
||||||||||||||
|
|
|
|
|
|
|||||||||||
Net revenues |
|
|
|
|
|
|||||||||||
TFE |
$ |
24,352 |
|
$ |
23,604 |
|
|
$ |
73,678 |
|
$ |
69,348 |
|
|||
Photonics |
|
11,092 |
|
|
7,972 |
|
|
|
35,207 |
|
|
25,766 |
|
|||
Total net revenues |
|
35,444 |
|
|
31,576 |
|
|
|
108,885 |
|
|
95,114 |
|
|||
|
|
|
|
|
|
|||||||||||
Gross profit |
|
16,493 |
|
|
10,572 |
|
|
|
40,868 |
|
|
32,694 |
|
|||
Gross margin |
|
|
|
|
|
|||||||||||
TFE |
|
46.9 |
% |
|
30.6 |
% |
|
|
37.2 |
% |
|
36.5 |
% |
|||
Photonics |
|
45.7 |
% |
|
42.1 |
% |
|
|
38.3 |
% |
|
28.6 |
% |
|||
Consolidated |
|
46.5 |
% |
|
33.5 |
% |
|
|
37.5 |
% |
|
34.4 |
% |
|||
|
|
|
|
|
|
|||||||||||
Operating expenses |
|
|
|
|
|
|||||||||||
Research and development |
|
3,296 |
|
|
3,973 |
|
|
|
14,309 |
|
|
16,862 |
|
|||
Selling, general and administrative |
|
5,913 |
|
|
4,814 |
|
|
|
22,627 |
|
|
20,188 |
|
|||
Acquisition-related1 |
|
— |
|
|
(147 |
) |
|
|
7 |
|
|
(139 |
) |
|||
Total operating expenses |
|
9,209 |
|
|
8,640 |
|
|
|
36,943 |
|
|
36,911 |
|
|||
|
|
|
|
|
|
|||||||||||
Total operating income (loss) |
|
7,284 |
|
|
1,932 |
|
|
|
3,925 |
|
|
(4,217 |
) |
|||
|
|
|
|
|
|
|||||||||||
Operating income (loss) |
|
|
|
|
|
|||||||||||
TFE |
|
5,181 |
|
|
861 |
|
|
|
1,747 |
|
|
(1,335 |
) |
|||
Photonics |
|
3,321 |
|
|
1,406 |
|
|
|
6,434 |
|
|
440 |
|
|||
Corporate |
|
(1,218 |
) |
|
(335 |
) |
|
|
(4,256 |
) |
|
(3,322 |
) |
|||
Total operating income (loss) |
|
7,284 |
|
|
1,932 |
|
|
|
3,925 |
|
|
(4,217 |
) |
|||
|
|
|
|
|
|
|||||||||||
Interest income and other income (expense), net |
|
133 |
|
|
158 |
|
|
|
582 |
|
|
622 |
|
|||
Income (loss) before income taxes |
|
7,417 |
|
|
2,090 |
|
|
|
4,507 |
|
|
(3,595 |
) |
|||
Benefit from (provision for) income taxes |
|
(2,215 |
) |
|
7,893 |
|
|
|
(3,359 |
) |
|
7,176 |
|
|||
Net income |
$ |
5,202 |
|
$ |
9,983 |
|
|
$ |
1,148 |
|
$ |
3,581 |
|
|||
|
|
|
|
|
|
|||||||||||
Net income per share |
|
|
|
|
|
|||||||||||
Basic |
$ |
0.22 |
|
$ |
0.44 |
|
|
$ |
0.05 |
|
$ |
0.16 |
|
|||
Diluted |
$ |
0.22 |
|
$ |
0.44 |
|
|
$ |
0.05 |
|
$ |
0.16 |
|
|||
|
|
|
|
|
|
|||||||||||
Weighted average common shares outstanding |
|
|
|
|
|
|||||||||||
Basic |
|
23,275 |
|
|
22,790 |
|
|
|
23,063 |
|
|
22,519 |
|
|||
Diluted |
|
23,677 |
|
|
22,948 |
|
|
|
23,340 |
|
|
22,904 |
|
1 |
Amounts for all periods presented include changes in fair value of contingent consideration obligations associated with the Solar Implant Technology (SIT) acquisition in 2010. |
CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except par value) |
||||||||
|
|
|
||||||
|
(Unaudited) |
(see Note) |
||||||
ASSETS |
|
|||||||
|
|
|
||||||
Current assets |
|
|||||||
Cash, cash equivalents and short-term investments |
$ |
36,487 |
|
$ |
34,791 |
|
||
Accounts receivable, net |
|
28,619 |
|
|
27,717 |
|
||
Inventories |
|
24,907 |
|
|
30,597 |
|
||
Prepaid expenses and other current assets |
|
1,504 |
|
|
2,528 |
|
||
Total current assets |
|
91,517 |
|
|
95,633 |
|
||
|
|
|
||||||
Long-term investments |
|
5,537 |
|
|
4,372 |
|
||
Restricted cash |
|
787 |
|
|
1,169 |
|
||
Property, plant and equipment, net |
|
11,598 |
|
|
11,198 |
|
||
Operating lease right-of-use assets |
|
10,279 |
|
|
— |
|
||
Intangible assets, net |
|
274 |
|
|
889 |
|
||
Other long-term assets |
|
6,330 |
|
|
8,809 |
|
||
Total assets |
$ |
126,322 |
|
$ |
122,070 |
|
||
|
|
|
||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
||||||
|
|
|
||||||
Current liabilities |
|
|
||||||
Current operating lease liabilities |
$ |
2,524 |
|
$ |
— |
|
||
Accounts payable |
|
4,199 |
|
|
6,053 |
|
||
Accrued payroll and related liabilities |
|
6,488 |
|
|
4,689 |
|
||
Other accrued liabilities |
|
3,593 |
|
|
4,952 |
|
||
Customer advances |
|
4,007 |
|
|
14,314 |
|
||
Total current liabilities |
|
20,811 |
|
|
30,008 |
|
||
|
|
|
||||||
Non-current liabilities |
|
|
||||||
Non-current operating lease liabilities |
|
9,532 |
|
|
— |
|
||
Other long-term liabilities |
|
186 |
|
|
2,438 |
|
||
Total non-current liabilities |
|
9,718 |
|
|
2,438 |
|
||
|
|
|
||||||
Stockholders’ equity |
|
|
||||||
Common stock ( |
|
23 |
|
|
23 |
|
||
Additional paid-in capital |
|
188,290 |
|
|
183,204 |
|
||
|
|
(29,158 |
) |
|
(29,047 |
) |
||
Accumulated other comprehensive income |
|
424 |
|
|
378 |
|
||
Accumulated deficit |
|
(63,786 |
) |
|
(64,934 |
) |
||
Total stockholders’ equity |
|
95,793 |
|
|
89,624 |
|
||
Total liabilities and stockholders’ equity |
$ |
126,322 |
|
$ |
122,070 |
|
Note: Amounts as of |
RECONCILIATION OF GAAP TO NON-GAAP RESULTS (Unaudited, in thousands, except per share amounts) |
|
|||||||||||||||
|
Three months ended |
Year ended |
||||||||||||||
|
|
|
|
|
|
|||||||||||
Non-GAAP Income (Loss) from Operations |
|
|
|
|
|
|||||||||||
Reported operating income (loss) (GAAP basis) |
$ |
7,284 |
$ |
1,932 |
|
|
$ |
3,925 |
$ |
(4,217 |
) |
|||||
Change in fair value of contingent consideration obligations1 |
|
— |
|
|
(147 |
) |
|
|
7 |
|
|
(139 |
) |
|||
Restructuring charges2 |
|
— |
|
— |
|
|
|
— |
|
|
95 |
|
||||
Non-GAAP Operating Income (Loss) |
$ |
7,284 |
|
$ |
1,785 |
|
|
$ |
3,932 |
|
$ |
(4,261 |
) |
|||
|
|
|
|
|
|
|||||||||||
Non-GAAP Net Income (Loss) |
|
|
|
|
|
|||||||||||
Reported net income (GAAP basis) |
$ |
5,202 |
|
$ |
9,983 |
|
|
$ |
1,148 |
|
$ |
3,581 |
|
|||
Change in fair value of contingent consideration obligations1 |
|
— |
|
|
(147 |
) |
|
|
7 |
|
|
(139 |
) |
|||
Restructuring charges2 |
|
— |
|
|
— |
|
|
|
— |
|
|
95 |
|
|||
Reversal of a deferred tax asset valuation allowance3 |
|
— |
|
|
(7,909 |
) |
|
— |
|
|
(7,909 |
) |
||||
Income tax effect of non-GAAP adjustments4 |
|
— |
|
— |
|
|
— |
— |
|
|||||||
Non-GAAP Net Income (Loss) |
$ |
5,202 |
|
$ |
1,927 |
|
|
$ |
1,155 |
|
$ |
(4,372 |
) |
|||
|
|
|
|
|
|
|||||||||||
Non-GAAP Net Income (Loss) Per Diluted Share |
|
|
|
|
|
|||||||||||
Reported net income per diluted share (GAAP basis) |
$ |
0.22 |
|
$ |
0.44 |
|
|
$ |
0.05 |
|
$ |
0.16 |
|
|||
Change in fair value of contingent consideration obligations1 |
$ |
— |
|
$ |
(0.01 |
) |
|
$ |
— |
|
$ |
(0.01 |
) |
|||
Restructuring charges2 |
$ |
— |
|
$ |
— |
|
|
$ |
— |
|
$ |
— |
|
|||
Reversal of a deferred tax asset valuation allowance3 |
$ |
— |
|
$ |
(0.34 |
) |
|
$ |
— |
|
$ |
(0.35 |
) |
|||
Non-GAAP Net Income (Loss) Per Diluted Share |
$ |
0.22 |
|
$ |
0.08 |
|
|
$ |
0.05 |
|
$ |
(0.19 |
) |
|||
Weighted average number of diluted shares |
|
23,677 |
|
|
22,948 |
|
|
|
23,340 |
|
|
22,904 |
|
1 |
Results for all periods presented include changes in fair value of contingent consideration obligations associated with the Solar Implant Technology (SIT) acquisition in 2010. |
|
2 |
Results for the year ended |
|
3 |
Results for the fourth quarter and year ended |
|
4 |
The amount represents the estimated income tax effect of the non-GAAP adjustments. The Company calculated the tax effect of non-GAAP adjustments by applying an applicable estimated jurisdictional tax rate to each specific non-GAAP item. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200129005194/en/
Chief Financial Officer
(408) 986-9888
Investor Relations
(530) 265-9899
Source: